The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
January 8th 2025
Nurse-led care effectively reduces disease activity and improves self-efficacy in patients with rheumatoid arthritis, delivering comparable outcomes to rheumatologist-led care and usual care while easing health care burdens.
Predictors of Severe COVID-19 Infection, Mortality in Patients With MM, AL Identified
November 29th 2022Their findings, say the researchers, offer useful insights into the outcomes and risks of severe disease and mortality in patients who have multiple myeloma (MM) or amyloidosis (AL) with underlying monoclonal gammopathy who contract COVID-19.
Read More
MDD Treatment Alternatives Explore Potential of Cannabis, Psychedelics
November 28th 2022Stemming from recent data on a potential link between major depressive disorder (MDD) and inflammation, research is starting to turn toward alternatives that can treat the disease through anti-inflammatory effects, including ketamine, cannabinoids, and psychedelics.
Read More
CBD May Improve Neurologic, Cognitive, QOL Outcomes in Sturge-Weber Syndrome
November 28th 2022A small, prospective, open-label trial found evidence of improved quality of life (QOL) and clinical outcomes among patients with treatment-resistant Sturge-Weber syndrome when they were treated with CBD.
Read More
Motor Function Continues to Improve in Second Year of Risdiplam Treatment for SMA
November 26th 2022Detailing findings from the secondary end points of the FIREFISH trial at 24 months, the researchers found that risdiplam treatment was associated with continued improvements in motor function and the achievement of development motor milestones.
Read More
Empagliflozin Has Similar Efficacy Across Subgroups, More Data Needed in CKD: Dr Jennifer Green
November 26th 2022Data on empagliflozin in chronic kidney disease (CKD) showed the drug had similar efficacy across subgroups, but more data is needed to really understand the benefit of the drug in CKD, said Jennifer Green, MD, professor of medicine at Duke University School of Medicine, member of Duke Clinical Research Institute, and EMPA-KIDNEY collaborator.
Watch
FGFR Inhibitors Show Promise in Cholangiocarcinoma but Face Acquired Resistance
November 25th 2022There are currently 3 FDA-approved therapies to treat cholangiocarcinoma with FGFR2 fusion or rearrangement, but these therapies face the development of resistance. Studies are underway to identify ways to overcome this resistance.
Read More
Liz Lightstone, MBBS, PhD, FRCP, professor of renal medicine for the Faculty of Medicine, Imperial College London, discussed how the potential teratogenic effects of novel therapies being investigated for lupus nephritis can impede clinical trial recruitment for women of childbearing age.
Watch
Low-Calorie Ketogenic Diet Improved Body Composition, Gut Microbiota Profile in T2D
November 23rd 2022Different dietary approaches were able to improve the state of health in patients with type 2 diabetes (T2D), with very-low-calorie ketogenic diets demonstrating better results on gut microbiota profile.
Read More
Drops in Serum Phosphate Levels May Help Predict Severe CRS After CAR T
November 23rd 2022A new study has found that a drop in serum inorganic phosphate (iP) was an early predictor of severe cytokine release syndrome (CRS), suggesting that monitoring serum iP levels could help promote safer management of the most common toxicity associated with chimeric antigen receptor (CAR) T-cell therapy.
Read More